Dr. Hafron on the “buzz” surrounding the 2021 LUGPA annual meeting

"Looking at data, if you apply IsoPSA in a consistent manner, based on the studies published, you'll see up to a 55% reduction in unnecessary biopsies," says Jason M. Hafron, MD.

Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.

“Overall, our results continue to support the use of lenvatinib and pembrolizumab as a current standard treatment option in the first-line treatment of [patients with] kidney cancer," says Viktor Grünwald, MD, PhD.

Adam B. Weiner, MD, and Ruchika Talwar, MD, discuss some of the notable urologic oncology abstracts that were presented at the 2023 AUA meeting.

“The HERCULES trial is the first trial to demonstrate the efficacy of immune checkpoint inhibitors in [patients with] advanced penile cancer with [a] manageable safety profile," says Fernando Cotait Maluf, MD.

Results presented from a phase 1/2 trial of ARV-766 demonstrated efficacy and tolerability in patients whose metastatic castration-resistant prostate cancer progressed after androgen receptor pathway inhibitor therapy.